Fertility drugs, reproductive strategies and ovarian cancer risk

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Tomao, Federica ^a   Lo Russo, Giuseppe ^a   Spinelli, Gian Paolo ^a   Stati, Valeria ^a   Prete, Alessandra Anna ^a   Prinzi, Natalie ^a   Sinjari, Marsela ^a   Vici, Patrizia ^b   Papa, Anselmo ^a   Chiotti, Maria Stefania ^a   Benedetti Panici, Pierluigi ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Clomiphene citrate; Fertility drugs; in vitro fertilization; Ovarian cancer; Ovarian stimulation

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; CLOMIFENE; FERTILITY PROMOTING AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COCHRANE LIBRARY; EMBASE; FEMALE FERTILITY; FERTILIZATION IN VITRO; HUMAN; MEDLINE; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; ADVERSE EFFECTS; CHEMICALLY INDUCED; FEMALE; INFERTILITY, FEMALE; OVARY TUMOR; RISK FACTOR;

CLOMIPHENE; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84901002049     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-51     Document Type: Review

References (71)

1. National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA, PLoS Med 2012 9 12 1001356 10.1371/journal.pmed.1001356 23271957
2. Outline for a national plan for the prevention, detection and management of infertility. Outline Version 050710. CDC, 2010 1 1 44 http://www.cdc.gov/art/ PDF/NationalAction-Plan.pdf. (accessed 30 June 2012)
3. Breast cancer risk after exposure to fertility drugs. Lo Russo G, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, Vici P, Codacci Pisanelli G, Tomao F, Expert Rev Anticancer Ther 2013 13 2 149 157 10.1586/era.12.181 23406556
4. Ovarian epithelial tumors and reproductive factors: a systematic review. Schüler S, Ponnath M, Engel J, Ortmann O, Arch Gynecol Obstet 2013 287 6 1187 1204 10.1007/s00404-013-2784-1 23503972
5. IVF and breast cancer: a systematic review and meta-analysis. Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET, Hum Reprod Update 2014 20 1 106 123 10.1093/humupd/dmt034 23884897
6. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA, Am J Obstet Gynecol 2005 193 3 Pt 1 668 674 16150258 (Pubitemid 41261460)
7. Parity, age at first childbirth, and risk of ovarian cancer. Adami HO, Hsieh CC, Lanbe M, Trichopoulos D, Leon D, Persson I, Ekbon A, Janson PO, Lancet 1994 344 1250 1254 10.1016/S0140-6736(94)90749-8 7967985 (Pubitemid 24334680)
8. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Risch HA, Marrett LD, Howe GR, Am J Epidemiol 1994 140 7 585 597 7942759 (Pubitemid 24313016)
9. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH, Am J Epidemiol 2002 155 3 217 224 10.1093/aje/155.3.217 11821246 (Pubitemid 34117299)
10. Fertility drugs and risk of epithelial ovarian cancer in Italy. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, Parazzini F, Hum Reprod 1994 9 9 1673 1675 7836516 (Pubitemid 24291081)
11. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG, Am J Epidemiol 2004 160 11 1070 1078 10.1093/aje/kwh315 15561986 (Pubitemid 39557459)
12. Use of fertility drugs and risk of ovarian cancer. Parazzini F, Pelucchi C, Negri E, Franceschi S, Talamini R, Montella M, La Vecchia C, Hum Reprod 200 2001 16 7 1372 1375 10.1093/humrep/16.7.1372 (Pubitemid 32640310)
13. Treatment for infertility and risk of invasive epithelial ovarian cancer. Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG, Hum Reprod 1997 12 10 2159 2161 10.1093/humrep/12.10.2159 9402274 (Pubitemid 27494022)
14. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN, Fertil Steril 1997 67 6 1005 1012 10.1016/S0015-0282(97)81431-8 9176436 (Pubitemid 27241890)
15. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. IV. Invasive epithelial ovarian cancer in with woman. Whittemore AS, Harris R, Itnyre J, Am J Epidemiol 1992 136 10 1184 1203 1476141 (Pubitemid 23026890)
16. Ovulation induction treatment and risk of borderline ovarian tumors. Cusidó M, Fábregas R, Pere BS, Escayola C, Barri PN, Gynecol Endocrinol 2007 23 7 373 376 10.1080/09513590701350341 17701767 (Pubitemid 47301185)
17. Cancer incidence in a cohort of infertile women. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B, Am J Epidemiol 1998 147 11 1038 1042 10.1093/oxfordjournals.aje.a009397 9620047
18. Use of clomiphene citrate in women. Practice Committee of the American Society for Reproductive Medicine, Fertil Steril 2004 82 1S 90 96
19. Use of clomiphene citrate in infertile women: a committee opinion. Practice Committee of the American Society for Reproductive Medicine, Fertil Steril 2013 100 2 341 348 23809505
20. A pharmacological review of selective oestrogen receptor modulators. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr, Hum Reprod Update 2000 6 3 212 224 10.1093/humupd/6.3.212 10874566 (Pubitemid 30348890)
21. Ovarian tumors in a cohort of infertile women. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG, N Engl J Med 1994 147 12 1038 1042
22. Ovarian epithelial neoplasia after hormonal infertility treatment: long-trm follow-up of historical cohort in Sweden. Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I, Fertil Steril 2009 91 4 1152 1158 10.1016/j.fertnstert.2008.01.073 18371964
23. Cancer incidence following treatment for infertility at a clinic in the UK. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL, Hum Reprod 2002 17 8 2209 2213 10.1093/humrep/17.8.2209 12151460
24. Cancer risk after exposure to treatments for ovulation induction. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, Harlap S, Paltiel O, Am J Epidemiol 2009 169 3 365 375 19037008
25. Fertility drugs and the risk of breast and ovarian cancers: results of a longterm follow-up study. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A, Fertil Steril 1999 71 5 853 859 10.1016/S0015-0282(99) 00085-0 10231045 (Pubitemid 29206910)
26. Ovarian cancer risk associated with varying causes of infertility. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL, Fertil Steril 2004 82 2 405 414 10.1016/j.fertnstert.2004.02.109 15302291 (Pubitemid 39092042)
27. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large US infertility cohort. Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA, Fertil Steril 2013 100 6 1660 1666 10.1016/j.fertnstert.2013.08.008 24011610
28. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. Jensen A, Sharif H, Frederiksen K, Kjaer SK, BMJ 2009 338 249 10.1136/bmj.b249 19196744
29. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Silva Idos S, Wark PA, McCormack VA, Mayer D, Overton C, Little V, Nieto J, Hardiman P, Davies M, MacLean AB, Br J Cancer 2009 100 11 1824 1831 10.1038/sj.bjc.6605086 19436296
30. New approaches to ovarian stimulation. Diedrich K, Felberbaum R, Hum Reprod 1998 13 3 1 13
31. Fertility drug therapies: past, present, and future. Leibowitz D, Hoffman J, J Obstet Gynecol Neonatal Nurs 2000 29 2 201 210 10.1111/j.1552-6909.2000. tb02040.x 10750686
32. A new era in ovulation induction. Holzer H, Casper R, Tulandi T, Fertil Steril 2006 85 2 277 284 10.1016/j.fertnstert.2005.05.078 16595197 (Pubitemid 43170893)
33. Ovarian stimulation in assisted reproduction. Gips H, Hormel P, Hinz V, Andrologia 1996 28 1 3 7 (Pubitemid 27041759)
34. Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovariansurface epithelium. Hilliard TS, Modi DA, Burdette JE, Int J Mol Sci 2013 14 3 4762 4782 10.3390/ijms14034762 23449028
35. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Lerner-Geva L, Rabinovici J, Olmer L, Blumstein T, Mashiach S, Lunenfeld B, Gynecol Endocrinol 2012 28 10 809 814 10.3109/09513590.2012.671391 22475084
36. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Rizzuto I, Behrens RF, Smith LA, Cochrane Database Syst Rev 2013 8 D008215 23943232
37. GnRH antagonists in IVF. Kolibianakis EM, Tarlatzis B, Devroey P, Reprod Biomed Online 2005 10 6 705 712 10.1016/S1472-6483(10)61113-3 15969996 (Pubitemid 40803413)
38. Choosing the right stimulation protocol for in vitro fertilization- embryo transfer in poor, normal, and hyper-responders. Check JH, Slovis B, Clin Exp Obstet Gynecol 2011 38 4 313 317 22268260
39. Ovulation induction in IVF. Oehninger S, Minerva Ginecol 2011 63 2 137 156 21508903
40. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. Zarek SM, Muasher SJ, Fertil Steril 2011 95 8 2449 2455 10.1016/j.fertnstert.2011.04.041 21550037
41. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer-a systematic review and meta-analysis. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET, Hum Reprod Update 2013 19 2 105 112 10.1093/humupd/dms051 23255514
42. Meta-analysis on the possible association between in vitro fertilization and cancer risk. Li LL, Zhou J, Qian XJ, Chen YD, Int J Gynecol Cancer 2013 23 1 16 24 10.1097/IGC.0b013e318277608b 23211423
43. The possible association between in vitro fertilization treatments and cancer development. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A, Int J Gynecol Cancer 2003 13 1 23 27 10.1046/j.1525-1438.2003.13041.x 12631215 (Pubitemid 36292720)
44. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Venn A, Wartson L, Lumley J, Giles G, King C, Healy D, Lancet 1995 346 8981 995 1000 10.1016/S0140-6736(95)91687-3 7475593
45. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Venn A, Watson L, Bruinsma F, Giles G, Healy D, Lancet 1999 354 9190 1586 1590 10.1016/S0140-6736(99)05203-4 10560672 (Pubitemid 29515949)
46. Malignancies among women who gave birth after in vitro fertilization. Källén B, Finnström O, Lindam A, Nilsson E, Nygren KG, Olausson PO, Hum Reprod 2011 26 1 253 258 10.1093/humrep/deq307 21088017
47. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B, Fertil Steril 2002 77 2 324 327 10.1016/S0015-0282(01)02986-7 11821091 (Pubitemid 34083556)
48. The Omega Project Group. Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilization in a cohort of 25,152 women. Klip H, Burger CW, Van Leeuwen FE, Enschede Netherlands PrintPartners Ipskamp BV 2002 1 55 82
49. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Hum Reprod 2011 26 12 3456 3465 10.1093/humrep/ der322 22031719
50. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E, Hum Reprod 2012 27 4 1149 1155 10.1093/humrep/des031 22343550
51. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G, Fertil Steril 2013 99 5 1189 1196 10.1016/j.fertnstert.2012.12.029 23375197
52. Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. Asch RH, Greenblatt RB, J Reprod Med 1976 17 3 175 180 787524
53. Follicular stimulation and ovarian cancer. Kulkarni R, McGarry JM, BMJ 1989 299 6701 740
54. Infertility and ovarian cancer. Chatterjee SK, J Indian Med Assoc 1999 97 2 69 10549200
55. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M, Acta Obstet Gynecol Scand 2004 83 12 1104 1111 10.1080/j.0001-6349. 2004.00669.x 15548140 (Pubitemid 39626183)
56. Ovarian hyperstimulation syndrome and prophylactic human embryo cryopreservation: analysis of reproductive outcome following thawed embryo transfer. Sills ES, McLoughlin LJ, Genton MG, Walsh DJ, Coull GD, Walsh AP, J Ovarian Res 2008 1 1 7 10.1186/1757-2215-1-7 19014420
57. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG, Fertil Steril 1996 65 1 13 18 8557128 (Pubitemid 26006641)
58. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih IM, Am J Surg Pathol 2010 34 3 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
59. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Kurman RJ, Ann Oncol 2013 24 10 16 21
60. Determinants of ovarian cancer risk. Inferences regarding pathogenesis. Cramer DW, Welch WR, J Natl Cancer Inst 1983 71 4 717 721 6578367 (Pubitemid 14232385)
61. Incessant ovulation: a factor in ovarian neoplasia? Fathalla MF, Lancet 1971 2 7716 163 4104488
62. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Whittemore AS, Harris R, Itnyre J, Am J Epidemiol 1992 136 10 1212 1220 1476143 (Pubitemid 23026892)
63. Increased cell division as a cause of human cancer. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE, Cancer Res 1990 50 23 7415 7421 2174724
64. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, Terada KY, Goodman MT, Am J Epidemiol 2005 161 4 321 329 10.1093/aje/kwi046 15692075 (Pubitemid 40256203)
65. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC, J Natl Cancer Inst 1992 84 8 592 601 10.1093/jnci/84.8.592 1556770
66. Fung Kee Fung M, Rosenwaks Z: Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Kashyap S, Moher D, Obstet and Gynecol 2004 103 4 785 794 10.1097/01.AOG.0000119226.39514.1d (Pubitemid 40459044)
67. Current role and safety profile of aromatase inhibitors in early breast cancer. Tomao F, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L, Panici PB, Tomao S, Expert Rev Anticancer Ther 2011 11 8 1253 1263 10.1586/era.11.96 21916579
68. Aromatase inhibitors for female infertility: a systematic review of the literature. Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D, Reprod Biomed Online 2009 19 4 456 471 10.1016/j.rbmo.2009.06.008 19909585
69. Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate: a systematic review and meta-analysis. Polyzos NP, Tzioras S, Mauri D, Tsappi M, Cortinovis I, Tsali L, Casazza G, Obstet Gynecol Surv 2008 63 7 472 479 10.1097/OGX.0b013e31817d4e8d 18559123
70. Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy. Tomao F, Benedetti Panici P, Tomao S, J Clin Oncol 2012 30 26 3310 3311
71. Ovarian function, reproduction and strategies for fertility preservation after breast cancer. Tomao F, Spinelli GP, Panici PB, Frati L, Tomao S, Crit Rev Oncol Hematol 2010 76 1 1 12 10.1016/j.critrevonc.2009.12.005 20185328